Last week, Galmed Pharmaceuticals (NASDAQ:GLMD) shares climbed as high as $9.90 per share this week, up approximately 7% on the day after the company released updated phase IIb results for Aramchol, the company’s treatment for NASH (non-alcoholic steatohepatitis). Galmed reported […]
This content is for members only